Tumor imaging with X-rays and other high energy sources using as contrast agents photon-emitting phosphors having therapeutic properties

Patent metadata

Field	Value
Publication number	US-10596387-B2
Application number	US-201515307766-A
Country	US
Kind code	B2
Filing date	Apr 22, 2015
Priority date	Apr 8, 2007
Publication date	Mar 24, 2020
Grant date	Mar 24, 2020

Abstract

A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.

First claim

The invention claimed is:

1. A method for imaging and treating a disease in a human or animal body, comprising:
infusing a diseased site with a photoactivatable drug and a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast;
irradiating the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body; and
producing images of the diseased site and controlling a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site thus activating the photoactivatable drug.

2. The method of claim 1 , wherein irradiating comprises irradiating with x-rays from a peak applied cathode voltage at or below 300 kVp, at or below 200 kVp, at or below 120 kVp, at or below 105 kVp, at or below 80 kVp, at or below 70 kVp, at or below 60 kVp, at or below 50 kVp, at or below 40 kVp, at or below 30 kVp, at or below 20 kVp, at or below 10 kVp, or at or below 5 kVp.

3. The method of claim 1 , wherein the phosphors comprise:
a first plurality of energy-converting particles in the medium which, upon radiation from the x-ray source, radiate at a first energy lower than the x-ray source; and
a second plurality of energy-converting particles which, upon radiation from the x-ray source, radiate at a second energy lower than the x-ray source.

4. The method of claim 3 , wherein
a combination of the first and second plurality of energy-converting particles comprises a weighted composition, and
emission from the weighted composition activates the photoactivatable drug.

5. The method of claim 4 , wherein emission overlaps an absorption spectrum of the photoactivatable drug.

6. The method of claim 1 , wherein infusing comprises injecting the phosphors nearby the diseased site for illumination of the photoactivatable drug to treat the diseased site.

7. The method of claim 6 , wherein the phosphors injected nearby the diseased site comprise a mixture of micron-size and nanometer-size particles.

8. The method of claim 1 , further comprising:
externally applying an electric field or a magnetic field distribution which concentrates the phosphors at the diseased site.

9. The method of claim 1 , wherein the irradiating comprises irradiating with an x-ray or high energy electron source utilizing carbon nanotubes as a source of electrons.

10. The method of claim 1 , further comprising assembling said images of the diseased site into tomographic views of the diseased site.

11. The method of claim 10 , wherein assembling comprises assembling images of a tumor or a malignancy.

12. The method of claim 1 , wherein the phosphors comprise at least one of:
phosphor particles;
ionic doped phosphor particles;
single crystal or poly-crystalline powders;
single crystal or poly-crystalline monoliths;
scintillator particles;
a metallic shell encapsulating at least a fraction of a surface of the phosphors;
a semiconductor shell encapsulating at least a fraction of a surface of the phosphors; and
an insulator shell encapsulating at least a fraction of a surface of the phosphors; and
phosphors of a distributed particle size.

13. The method of claim 12 , wherein the metallic shell comprises a plasmonic shell configured to enhance at least one of said absorption or said emission.

14. The method of claim 1 , wherein the phosphors comprise particles having a dielectric core.

15. The method of claim 14 , wherein the phosphors comprise a metallic shell at least partially covering said dielectric core and comprises at least one of Au, Ag, Cu, Ni, Pt, Pd, Co, Ru, Rh, or a combination thereof.

16. The method of claim 1 , wherein the phosphors comprise at least one of Y 2 O 3 ; ZnS; ZnSe; MgS; CaS; Mn, Er ZnSe; Mn, Er MgS; Mn, Er CaS; Mn, Er ZnS; Mn,Yb ZnSe; Mn,Yb MgS; Mn, Yb CaS; Mn,Yb ZnS:Tb 3+ , Er 3+ ; ZnS:Tb 3+ ; Y 2 O 3 :Tb 3+ ; Y 2 O 3 :Tb 3+ , Er3 + ; ZnS:Mn 2+ ; ZnS:Mn,Er 3+ ; CaWO 4 , YaTO 4 , YaTO 4 :Nb, BaSO 4 :Eu, La 2 O 2 S:Tb, BaSi 2 O 5 :Pb, NaI(Tl), CsI(Tl), CsI(Na), CsI(pure), CsF, KI(Tl), LiI(Eu), BaF 2 , CaF, CaF 2 (Eu), ZnS(Ag), CaWO 4 , CdWO 4 , YAG(Ce) (Y 3 Al 5 O 12 (Ce)), BGO bismuth germanate, GSO gadolinium oxyorthosilicate, LSO lutetium oxyorthosilicate, LaCl 3 (Ce), LaBr 3 (Ce), LaPO 4 ; Ce, Tb (doped), and Zn 2 SiO 4 :Mn with Mn doped between 0.05-10%.

17. The method of claim 1 , wherein the phosphors comprise at least one of down conversion or up conversion media, and combinations and agglomerations thereof with or without plasmonic agents.

18. The method of claim 1 , wherein infusing comprises administering the photoactivatable drug in accordance with a volume of the diseased site.

19. The method of claim 18 , wherein
an amount of the phosphors in the pharmaceutical carrier ranges from 0.1 to 0.66 milligrams of phosphor per cm 3 of the volume of the diseased site, and
a concentration of the photoactivatable drug in the pharmaceutical carrier ranges from 10 μg/mL to 50 μg/mL.

20. The method of claim 1 , wherein the photoactivatable drug comprises a psoralen compound mixed with the phosphors.

21. The method of claim 1 , wherein the photoactivatable drug is selected from psoralens, pyrene cholesteryloleate, acridine, porphyrin, fluorescein, rhodamine, 16-diazorcortisone, ethidium, transition metal complexes of bleomycin, transition metal complexes of deglycobleomycin organoplatinum complexes, alloxazines, vitamin Ks, vitamin L, vitamin metabolites, vitamin precursors, naphthoquinones, naphthalenes, naphthols and derivatives thereof having planar molecular conformations, porphorinporphyrins, dyes and phenothiazine derivatives, coumarins, quinolones, quinones, and anthroquinones.

22. The method of claim 1 , wherein the photoactivatable drug comprises a psoralen, a coumarin, a porphyrin or a derivative thereof.

23. The method of claim 1 , wherein the photoactivatable drug comprises s 8-MOP, TMP, or AMT.

24. The method of claim 1 , wherein the photoactivatable drug comprises one selected from 7,8-dimethyl-10-ribityl, isoalloxazine, 7,8,10-trimethylisoalloxazine, 7,8-dimethylalloxazine, isoalloxazine-adenine dinucleotide, alloxazine mononucleotide, aluminum (III) phthalocyanine tetrasulonate, hematophorphyrin, and phthadocyanine.

25. The method of claim 1 , wherein the photoactivatable drug is coupled to a carrier that is capable of binding to a receptor at the diseased site.

26. The method of claim 25 , wherein the carrier is one selected from insulin, interleukin, thymopoietin or transferrin.

27. The method of claim 25 , wherein the receptor is one selected from nucleic acids of nucleated cells, antigenic sites on nucleated cells, or epitopes.

28. The method of claim 1 , wherein the photoactivatable drug has an affinity for a tumor at the diseased site.

29. The system of claim 28 , wherein the photoactivatable drug is capable of being absorbed by a tumor at the diseased site.

30. The method of claim 29 , wherein the photoactivatable drug is a DNA intercalator or a halogenated derivative thereof.

31. The method of claim 1 , wherein irradiating comprises delivering a controlled radiation dose to the phosphors for activation of the photoactivatable drug.

Assignees

• Immunolight Llc
• Univ Duke

Inventors

• Walder Harold
• Bourke Frederic A
• Fathi Zakaryae
• Beyer Wayne F
• Dewhirst Mark W
• Oldham Mark
• Adamson Justus
• Nolan Michael

Classifications

• A61N2005/1098

  Enhancing the effect of the particle by an injected agent or implanted device · CPC title

• A61N5/1081

  Rotating beam systems with a specific mechanical construction, e.g. gantries · CPC title

• A61N2005/0627

  Dose monitoring systems and methods · CPC title

• A61K41/17

  by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays · CPC title

• A61N2005/0662

  Visible light · CPC title